Status:
COMPLETED
NATURAL KILLER CELLS IN IMMUNOLOGIC THROMBOCYTOPENIC PURpura of Adults
Lead Sponsor:
Assistance Publique Hopitaux De Marseille
Conditions:
Immunologic Thrombcytopenic Purpura (ITP) Adults
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Immunologic thrombcytopenic purpura (ITP) affects both children and adults. The incidence is estimated in adults about 1,6/100 000/per year. Chronic and relapsing forms of the disease that represent 7...
Detailed Description
Natural Killer cells (NK) cells, who are now implicated in the pathophysiology of several autoimmune diseases, express CD16 and display antibody dependent cytotoxicty. Moreover NK cells are present in...
Eligibility Criteria
Inclusion
- ITP patients,platelets less than 50000 G/L
Exclusion
- Secondary ITP (VIH, VHC...)
- treatment with Immunosuppressive agents except corticoids (10 mg/day)
- treatment with Ig IV less than 3 weeks
- treatment with Rifuximab less than 6 months
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2014
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT01172015
Start Date
September 1 2010
End Date
June 1 2014
Last Update
April 22 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
APHM
Marseille, France, 13